New Breast Cancer Gene identified. BCL11A drives triple negative breast cancer.

bgeneResearchers from the Wellcom Trust Sanger Institute have identified a new breast cancer gene called BCL11A associated with driving the development and progression of triple negative breast cancer.

The statistics reflect that one in five patients is affected by triple negative breast cancer, defined as cancer which lacks the three receptor proteins that respond to hormone therapies used for other sub-types of breast cancer. The treatment for triple negative breast cancer is poor.

The study focused on analyzing breast cancer from 3000 patients. In doing so they found the BCL11A gene, which was extremely active in triple negative cancers, affecting eight out of ten patients with basal like breast cancer and was associated with a more advanced grade of tumor.

“Our understanding of that drive stem cell development led us to search for consequences when these go wrong,” said Dr Pentao Liu, senior author on the study, from the Wellcome Trust Sanger Institute. “It had all the hallmarks of a novel breast cancer gene.”

“Our gene studies in clearly marked BCL11A as a novel driver for triple-negative ,” said Dr Walid Khaled, joint first author on the study from the Wellcome Trust Sanger Institute and University of Cambridge. “We also showed that adding an active human BCL11A gene to human or mouse breast cells in the lab drove them to behave as cancer cells”. “As important, when we reduced the activity of BCL11A in three samples of human triple-negative breast cancer cells, they lost some characteristics of cancer cells and became less tumorigenic when tested in mice. So by increasing BCL11A activity we increase cancer-like behaviour; by reducing it, we reduce cancer-like behaviour.”

Upon inactivating the BCL11A gene in mice, none of the mice developed tumours in their mammary gland, compared to all of the untreated mice who developed tumors. It was also determined that BCL11A is required for normal development of breast stem cells and progenitors, which are thought to be the cells that, when mutated, give rise to basal-like breast cancer.


BLC11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells, Walid Khaled, et al., Nature Communications, doi: 10.1038/ncomms6987, published online 9 January 2015.

Be Sociable, Share!

    Leave a Reply

    Your email address will not be published. Required fields are marked *